Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Seratrodast

Home DrugsSeratrodast

Experimental

Small Molecule

Seratrodast

Unknown Manufacturer

Seratrodast (INN) is a thromboxane receptor antagonist used primarily in the treatment of asthma.

Generate AI report

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Overview

Seratrodast (INN) is a thromboxane receptor antagonist used primarily in the treatment of asthma.

Indications

参阅扎普司特。

Technical identifiers

Chemical Formula: C₂₂H₂₆O₄
CAS Number: 112665-43-7
UNII ID: 4U58JM421N

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

Production method of seratrodast
Applicant: ZHANG YUNPriority: 2013
CN
COMBINATION FOR USE IN THE TREATMENT OF ATHEROSCLEROSIS COMPRISING A MAST CELL INHIBITOR AND RAMATROBAN OR SERATRODAST
Applicant: CARDOZ ABPriority: 2007
WO
'Sqiqu site' ramification and its preparing method as well as its activity of anti asthma
Applicant: UNIV CHINA PHARMACYPriority: 2003
CN
NEW COMBINATION FOR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS
Applicant: CARDOZ ABPriority: 2008
WO
NEW COMBINATION FOR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS
Applicant: CARDOZ ABPriority: 2008
WO
Pharmacological Treatments for Sleep Disorders (Apnoe) With Prostanoid Receptor Antagonists
Applicant: CARLEY DAVID WPriority: 2005
US
WO
3 publications